Metabolism - Clinical and Experimental
Volume 44, Issue 12 , Pages 1570-1576 , December 1995

Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: Influence on muscle glycogen synthase and insulin receptor kinase activity

  • Leif Breum

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Leif Breum, MD, Department of Endocrinology E, Frederiksberg Hospital, University of Copenhagen, Ndr. Fasanvej 57, DK-2000 Frederiksberg C, Denmark.
    • Departments of Internal Medicine and Endocrinology, Hvidovre Hospital and Frederiksberg Hospital, University of Copenhagen Copenhagen, Denmark
    • Research Department of Human Nutrition, Royal Veterinary and Agricultural University, Copenhagen, Denmark
    • The University Department of Endocrinology and Metabolism, Aarhus University Hospital, Aarhus, Denmark
    • ,
  • Ulla Bjerre

      Affiliations

    • Departments of Internal Medicine and Endocrinology, Hvidovre Hospital and Frederiksberg Hospital, University of Copenhagen Copenhagen, Denmark
    • Research Department of Human Nutrition, Royal Veterinary and Agricultural University, Copenhagen, Denmark
    • The University Department of Endocrinology and Metabolism, Aarhus University Hospital, Aarhus, Denmark
    • ,
  • Jens F. Bak

      Affiliations

    • Departments of Internal Medicine and Endocrinology, Hvidovre Hospital and Frederiksberg Hospital, University of Copenhagen Copenhagen, Denmark
    • Research Department of Human Nutrition, Royal Veterinary and Agricultural University, Copenhagen, Denmark
    • The University Department of Endocrinology and Metabolism, Aarhus University Hospital, Aarhus, Denmark
    • ,
  • Søren Jacobsen

      Affiliations

    • Departments of Internal Medicine and Endocrinology, Hvidovre Hospital and Frederiksberg Hospital, University of Copenhagen Copenhagen, Denmark
    • Research Department of Human Nutrition, Royal Veterinary and Agricultural University, Copenhagen, Denmark
    • The University Department of Endocrinology and Metabolism, Aarhus University Hospital, Aarhus, Denmark
    • ,
  • Arne Astrup

      Affiliations

    • Departments of Internal Medicine and Endocrinology, Hvidovre Hospital and Frederiksberg Hospital, University of Copenhagen Copenhagen, Denmark
    • Research Department of Human Nutrition, Royal Veterinary and Agricultural University, Copenhagen, Denmark
    • The University Department of Endocrinology and Metabolism, Aarhus University Hospital, Aarhus, Denmark

Received 19 November 1994 ,Accepted 28 March 1995.

References 

  1. Garattini S, Buczko W, Jori A, et al.  The mechanism of action of d-fenfluramine. Postgrad Med J. 1975;51:27–32 (suppl)
  2. Pijl H, Koppeschaar PF, Willekens FLA, et al.  Effect of serotonin reuptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. Int J Obes. 1991;15:237–242
  3. Levine LR, Enas GG, Thompson WL, et al.  Use of fluoxetine, a selective serotonin-uptake inhibitor. In: the treatment of obesity: A dose-response study. Int J Obes. 13:1989;p. 635–645
  4. Darga LL, Carrol-Michals L, Botsford SJ, et al.  Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr. 1991;54:321–325
  5. Goldstein DJ, Rampey AH, Dornseif BE, et al.  Fluoxetine. In: A randomized clinical trial in the maintenance of weight loss. Obes Res. 1:1993;p. 92–98
  6. Byerley WF. Fluoxetine, a selective serotonin reuptake inhibitor for the treatment of major depression. J Clin Psychopharmacol. 1988;8:12–115
  7. Kutnowski M, Daubresse JC, Friedman H, et al.  Fluoxetine therapy in obese diabetic and glucose intolerant patients. Int J Obes. 1992;16:S63–S66
  8. Potter van Loon BJ, Radder JK, Frolich M, et al.  Fluoxetine increases insulin action in obese nondiabetic and in obese noninsulin-dependent diabetic individuals. Int J Obes. 1992;16:79–85
  9. Gray DS, Fujioka K, Devine W, et al.  Fluoxetine treatment of the obese diabetics. Int J Obes. 1992;16:193–198
  10. Wise SD. Clinical studies with fluoxetine in obesity. Am J Clin Nutr. 1992;55:181S–184S
  11. Guy-Grand B, Apfelbaum M, Crepaldi G, et al.  International trial of long-term dexfenfluramine in obesity. Lancet. 1989;2:1142–1145
  12. Mathus-Vliegen EMH, Van de Vorde K, Kok AME, et al.  Dexfenfluramine in the treatment of severe obesity: A placebocontrolled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour. J Int Med. 1992;232:119–127
  13. Turtle JR, Burgess JA. Hypoglycemic action of fenfluramine in diabetes mellitus. Diabetes. 1973;22:858–867
  14. Scheen AJ, Paolisso G, Salvatore T, et al.  Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine. Diabetes Care. 1991;14:325–332
  15. Damsbo P, Madsbad S, Henriksen JE, et al.  Effect of weight loss and dexfenfluramine on glycemic control and glucose metabolism in obese NIDDM patients. Diabetes. 1991;40(suppl 1):307A; abstr
  16. Andersen PH, Richelsen B, Bak J, et al.  Influence of short-term dexfenfluramine therapy on glucose and lipid metabolism in obese non-diabetic patients. Acta Endocrinol (Copenh). 1993;128:251–258
  17. Bogardus C, Lillioja S, Stone K, et al.  Correlation between muscle glycogen synthase activity and in vivo insulin action in man. J Clin Invest. 1984;73:1185–1190
  18. Shulmann GI, Rothman DL, Jue T, et al.  Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med. 1989;322:223–228
  19. Caro JF, Sinha MK, Raju SM, et al.  Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. J Clin Invest. 1987;79:1330–1337
  20. Visser M, Seidell JC, Koppeschaar HPF, et al.  The effect of fluoxetine on body weight, body composition and visceral fat accumulation. Int J Obes. 1993;17:247–253
  21. Lukaski HC, Johnson PE, Bolonchuck WW, et al.  Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr. 1985;41:810–817
  22. Heitmann BL. Prediction of body water and fat in adult Danes from measurement of electrical bioimpedance. In: A validation study. Int J Obes. 14:1990;p. 789–802
  23. Bak JF, Schmitz O, Schwartz Sørensen N, et al.  Postreceptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients. Diabetes. 1989;38:1343–1350
  24. Bak JF, Møller N, Schmitz O, et al.  In vivo insulin action and muscle glycogen synthase activity in type 2 (non-insulin-dependent) diabetes mellitus: Effects of diet treatment. Diabetologia. 1992;35:777–784
  25. Freidenberg GR, Suter SL, Henry RR, et al.  Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. In: Effect of weight loss. J Clin Invest. 80:1988;p. 1398–1406
  26. Marcus MD, Wing RR, Ewing L, et al.  A double-blind, placebo-controlled trial of fluoxetine plus behaviour modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry. 1990;147:876–881
  27. Andersen T, Astrup A, Quaade F. Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: A randomized clinical trial. Int J Obes. 1992;16:35–40
  28. Astrup A, Breum L, Toubro S, et al.  The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. In: A double blind trial. Int J Obes. 16:1992;p. 269–277
  29. Saunders NH, Al-Zeibak S, Ryde SJS, et al.  The composition of weight loss in dieting obese females by electrical methods. Int J Obes. 1993;17:317–322
  30. Andersson B, Zimmermann ME, Hedner T, et al.  Haemodynamic, metabolic and endocrine effects of short-term dexfenfluramine treatment in young, obese women. Eur J Clin Pharmacol. 1991;40:249–254
  31. Kolanowski J, Younis LT, Van Butsele , et al.  Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients. Eur J Clin Pharmacol. 1992;42:599–606
  32. Stinson JC, Murphy CM, Andrews JF, et al.  An assessment of the thermogenic effects of fluoxetine in obese subjects. Int J Obes. 1992;16:391–395

☆ Supported by a grant from Eli Lilly & Co.

PII: 0026-0495(95)90077-2

Metabolism - Clinical and Experimental
Volume 44, Issue 12 , Pages 1570-1576 , December 1995

Article Tools